Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon
- PMID: 28756053
- PMCID: PMC5735030
- DOI: 10.1016/j.cgh.2017.07.023
Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon
Abstract
Background & aims: Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) have a high risk of colonic neoplasia. Neoplasia frequently develops in the proximal colon in patients with PSC. Histologic inflammation is an independent risk factor for the development of neoplasia; we investigated whether patients with UC and PSC have more subclinical disease activity than patients with UC alone.
Methods: We performed a retrospective analysis of data from 143 patients (205 examinations) with ulcerative pancolitis who were in clinical remission and treated at a tertiary medical center from May 2011 through May 2016. Endoscopic and histologic activity were compared between patients with PSC (from 36 examinations) and without PSC (from 169 examinations). Disease activity was scored per colonic segment using a modified Mayo endoscopic subscore and histologic assessment. In each colonic segment, differences in disease activity and the degree of discordance between endoscopic and histologic inflammation among UC patients with and without PSC were compared.
Results: Patients with UC-PSC had significantly more subclinical endoscopic (odds ratio [OR], 4.21; 95% CI, 1.67-10.63) and histologic activity (OR, 5.13; 95% CI, 2.25-11.68) in the right colon, as well as greater degree of histologic than endoscopic inflammation in the proximal colon (OR, 3.14, 95% CI, 1.24-7.97), compared with patients without PSC. Patients with UC-PSC had significantly less histologic activity in the rectum on multivariate analysis (OR, 0.24; 95% CI, 0.08-0.72).
Conclusions: Patients with UC and PSC who are in clinical remission are significantly more likely to have endoscopic and histologic inflammation in the right colon than patients with UC without PSC. Our findings provide insight into cause of colorectal cancer in UC patients with PSC.
Keywords: Histologic Inflammation; Inflammatory Bowel Disease; Mucosal Healing; Mucosal Inflammation.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures: The authors have no relevant conflicts of interest.
Figures

Similar articles
-
Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Clin Gastroenterol Hepatol. 2018 Jul;16(7):1098-1105.e1. doi: 10.1016/j.cgh.2018.01.020. Epub 2018 Mar 24. Clin Gastroenterol Hepatol. 2018. PMID: 29378308
-
Increased Active Inflammation in the Colon is Not a Reliable Predictor of an Elevated Risk of Dysplasia in Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis.Am J Surg Pathol. 2024 Sep 1;48(9):1154-1163. doi: 10.1097/PAS.0000000000002255. Epub 2024 May 29. Am J Surg Pathol. 2024. PMID: 38809303
-
Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study.Am J Surg Pathol. 2009 Jun;33(6):854-62. doi: 10.1097/PAS.0b013e318196d018. Am J Surg Pathol. 2009. PMID: 19295408
-
Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.Eur J Gastroenterol Hepatol. 2016 Apr;28(4):383-90. doi: 10.1097/MEG.0000000000000576. Eur J Gastroenterol Hepatol. 2016. PMID: 26938805 Review.
-
Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer.Semin Liver Dis. 2006 Feb;26(1):31-41. doi: 10.1055/s-2006-933561. Semin Liver Dis. 2006. PMID: 16496231 Review.
Cited by
-
Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis.Gastroenterol Rep (Oxf). 2021 Feb 5;9(3):274-275. doi: 10.1093/gastro/goab004. eCollection 2021 Jun. Gastroenterol Rep (Oxf). 2021. PMID: 34316379 Free PMC article. No abstract available.
-
Clinical association between inflammatory bowel disease and primary sclerosing cholangitis: what changes after colectomy and liver transplantation?eGastroenterology. 2025 Aug 10;3(3):e100199. doi: 10.1136/egastro-2025-100199. eCollection 2025. eGastroenterology. 2025. PMID: 40791845 Free PMC article. Review.
-
Gut microbiome in primary sclerosing cholangitis: A review.World J Gastroenterol. 2020 Jun 7;26(21):2768-2780. doi: 10.3748/wjg.v26.i21.2768. World J Gastroenterol. 2020. PMID: 32550753 Free PMC article. Review.
-
Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)-A European Society of Organ Transplantation (ESOT) Consensus Statement.Transpl Int. 2023 Sep 29;36:11729. doi: 10.3389/ti.2023.11729. eCollection 2023. Transpl Int. 2023. PMID: 37841645 Free PMC article.
-
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.Aliment Pharmacol Ther. 2018 Mar;47(6):753-762. doi: 10.1111/apt.14525. Epub 2018 Jan 29. Aliment Pharmacol Ther. 2018. PMID: 29377235 Free PMC article.
References
-
- Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–459. - PubMed
-
- Wong NA, Harrison DJ. Colorectal neoplasia in ulcerative colitis-recent advances. Histopathology. 2001;39:221–34. - PubMed
-
- Torres J, de Chambrun GP, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;34:497–508. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical